clinical Information

    • DRAMP ID

    • DRAMP18087

    • Sequence

    • Sequence Name

    • D2A21(Demegal)

    • Description

    • a 22-residue αhelix peptide

    • Activity

    • Unknown

    • Medical use

    • Anti-infective and antifungal

    • Stage of Development

    • Preclinical

    • Comments

    • 100% for the D2A21-treated animals, 50% for control-treated animals, 83% for Sulfamylon-treated animals, and 33% for SSD-treated animals.

    • Company

    • Par Advance Technologies, Inc.

    • Target Organism

      • The MCC(minimum cidal concentration of C. trachomatis) of peptide D2A21was 5 μM (18.32 μg/ml).The MCC of gel formulations containing 2% D2A21 was 0.2 mM (0.7 mg/ml).

    • Reference

      • Antimicrobial peptides: therapeutic potential. Expert Opin. Pharmacother. (2006).
      • In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis.Antimicrob. Agents Chemother(2002).(PMID: 11751108)
      • Treatment of infected wounds with the antimicrobial peptide D2A21.JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE(2003)(PMID: 12707542)